Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efatutazone plus Paclitaxel in Advanced Anaplastic Thyroid Cancer
NCT02152137Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Dec 2014
- Primary completion
- Feb 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efatutazone in anaplastic thyroid cancer (ATC), sponsored by Cancer and Leukemia Group B. Primary endpoint: Confirmed Response Rate up to 24 weeks. Started Dec 2014; status: completed.
02
Drugs
efatutazone
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT02152137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02152137.